Delamanid should be effective against highly resistant strains of M. tuberculosis, but uptake has been slow globally. In the endTB Observational Study, which enrolled one of the largest, most heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% experienced sputum culture conversion within six months.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: email@example.com.